Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ERSP reviews hoodia

This article was originally published in The Tan Sheet

Executive Summary

Claims that SmartBurn with Hoodia weight-loss supplement helps control appetite were adequately supported by studies cited by marketer Iovate Health Sciences International, the Electronic Retailing Self-Regulation Program (ERSP) concludes Sept. 5. The company submitted two peer-reviewed, double-blind, placebo-controlled studies to support claims such as "with the key ingredients in SmartBurn, you can lose up to 450% [more] weight than if you were to follow a diet and exercise plan alone." Although the group raised concerns about the use of the word "rapid" to describe the weight loss that took place, it concluded that it was satisfied that consumers would understand the time of product performance being relied on by the marketer in making the claim." An anonymous challenge prompted the review by ERSP...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel